Modern Bt Techniques - Florence 2016

IGR phase III trial

CONCLUSIONS : Cs 37 cGy/h versus 73 cGy/h

• No DRE for surgical difficulties at operation except for delayed surgery in stage II • No DRE for tumor sterilisation in specimen except for medium size tumors • No DRE for relapse free survical • Higher complications prevalence in the higher dose rate group

Haie et al., 1994